Medicare Plan For Lowering Insulin Costs Takes Aim At Benefit Design Instead Of List Prices
The new payment demonstration in Part D reflects the increasing recognition that insurance benefit design has a major impact on insulin affordability.
You may also be interested in...
Manufacturers are on board for ‘Part D Senior Savings Model’ that would set a $35 copay cap, but added risk corridor payments may be the key to getting PBMs to offer the enhanced plans focused on reducing insulin costs for patients.
Senate legislation taking aim at price increases faces uphill climb, but sponsors are hoping President Trump will mobilize more support among congressional Republicans in the coming year.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.